We are live on ! Find out more
ROIV icon

Roivant Sciences

205 hedge funds and large institutions have $6.38B invested in Roivant Sciences in 2023 Q3 according to their latest regulatory filings, with 52 funds opening new positions, 88 increasing their positions, 47 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

93% more first-time investments, than exits

New positions opened: 52 | Existing positions closed: 27

87% more repeat investments, than reductions

Existing positions increased: 88 | Existing positions reduced: 47

40% more funds holding in top 10

Funds holding in top 10: 1014 (+4)

27% more capital invested

Capital invested by funds: $5.02B → $6.38B (+$1.36B)

26% more call options, than puts

Call options by funds: $29.4M | Put options by funds: $23.3M

13% more funds holding

Funds holding: 181205 (+24)

4.08% more ownership

Funds ownership: 64.9%68.98% (+4.1%)

Holders
205
Holders Change
+24
Holders Change %
+13.26%
% of All Funds
3.25%
Holding in Top 10
14
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+40%
% of All Funds
0.22%
New
52
Increased
88
Reduced
47
Closed
27
Calls
$29.4M
Puts
$23.3M
Net Calls
+$6.07M
Net Calls Change
-$948K
Name Holding Trade Value Shares
Change
Change in
Stake
QF
1
QVT Financial
New York
$1.31B -$113M -10,000,000 -8%
Viking Global Investors
2
Viking Global Investors
Connecticut
$858M -$20.4M -1,804,399 -2%
SIAU
3
SB Investment Advisers (UK)
United Kingdom
$853M -$113M -10,000,000 -12%
Fidelity Investments
4
Fidelity Investments
Massachusetts
$454M +$32.9M +2,913,491 +8%
Morgan Stanley
5
Morgan Stanley
New York
$226M +$71.5M +6,324,915 +49%
BlackRock
6
BlackRock
New York
$207M +$60.5M +5,350,664 +43%
Wellington Management Group
7
Wellington Management Group
Massachusetts
$173M -$4M -353,579 -2%
PSC
8
Patient Square Capital
California
$148M
BBA
9
Baker Bros. Advisors
New York
$139M +$27.7M +2,448,579 +26%
T. Rowe Price Investment Management
10
T. Rowe Price Investment Management
Maryland
$124M +$120M +10,649,397 New
RCMNY
11
Rubric Capital Management (New York)
New York
$123M +$78.7M +6,963,562 +197%
State Street
12
State Street
Massachusetts
$121M +$8.9M +786,896 +8%
TSC
13
Two Seas Capital
New York
$92.4M +$63.8K +5,641 +0.1%
WP
14
Woodline Partners
California
$83.8M +$38.2M +3,377,382 +89%
Adage Capital Partners
15
Adage Capital Partners
Massachusetts
$72.4M -$55.3M -4,890,300 -44%
Vanguard Group
16
Vanguard Group
Pennsylvania
$65.4M +$38.9M +3,440,374 +159%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$61M +$28M +2,478,175 +90%
ACG
18
Anchorage Capital Group
New York
$56.4M
ACA
19
Avoro Capital Advisors
New York
$54.3M -$13.1M -1,155,000 -20%
OCA
20
Octagon Capital Advisors
New York
$51M +$5.23M +463,000 +12%
Janus Henderson Group
21
Janus Henderson Group
United Kingdom
$46.5M -$5.32M -470,924 -11%
FCM
22
Farallon Capital Management
California
$45M +$16.9M +1,498,400 +64%
PA
23
Perceptive Advisors
New York
$44.6M +$7.77M +687,720 +22%
T. Rowe Price Associates
24
T. Rowe Price Associates
Maryland
$43.4M +$41.4M +3,662,354 +7,306%
NIP
25
Nicholas Investment Partners
California
$35M +$8.28M +732,812 +32%

ROIV Hedge Fund Activity: Q3 2023 in Review

205 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Roivant Sciences (ROIV) for Q3 2023, worth a combined $6.38B — up 27% from $5.02B a quarter earlier.

Buyers outnumbered sellers: 52 funds opened new ROIV positions and 27 closed out — a net gain of 25 holders — while 88 added to existing stakes and 47 trimmed.

The largest buyer was T. Rowe Price Investment Management, opening a new position worth an estimated $120M. The largest seller was QVT Financial, cutting an estimated $113M.

  • 205 institutional investors held Roivant Sciences (ROIV) as of Q3 2023, up from 181 in Q2 2023.
  • Funds reported $6.38B of Roivant Sciences stock for Q3 2023, up 27% quarter-over-quarter.
  • 52 funds opened new Roivant Sciences positions in Q3 2023 and 27 closed out, a net change of +25 holders.
  • The largest Roivant Sciences buyer in Q3 2023 was T. Rowe Price Investment Management, an estimated $120M added.
  • The largest Roivant Sciences seller in Q3 2023 was QVT Financial, an estimated $113M sold.

Based on aggregated 13F filings for Q3 2023.